NHS Dudley Health Economy Medicines Formulary
Home > 5 Infections > 5.3 Antiviral drugs > 5.3.3 Viral hepatitis > 5.3.3.2 Chronic hepatitis C > Sofosbuvir for treating chronic hepatitis C - NICE TAG TA330

Sofosbuvir for treating chronic hepatitis C - NICE TAG TA330

1.1 Sofosbuvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1.

Table 1 Sofosbuvir for treating adults with chronic hepatitis C

 

Sofosbuvir in combination with peginterferon alfa and ribavirin

Sofosbuvir in combination with ribavirin

Genotype

Treatment history

Recommendation

Treatment history

Recommendation

Adults with genotype 1 HCV

All

Recommended

All

Not recommended

Adults with genotype 2 HCV

All

Not licensed for this population

Treatment-naive

Only recommended for people who are intolerant to or ineligible for interferon

Treatment-experienced

Recommended

Adults with genotype 3 HCV

Treatment-naive

Only recommended for people with cirrhosis

Treatment-naive

Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon

Treatment-experienced

Recommended

Treatment-experienced

Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon

Adults with genotype 4, 5 or 6 HCV

All

Only recommended for people with cirrhosis

All

Not recommended

HCV – hepatitis C virus

Treatment‑naive – the person has not had treatment for chronic hepatitis C

Treatment‑experienced – the person's hepatitis C has not adequately responded to interferon‑based treatment

1.2 People currently receiving treatment initiated within the NHS with sofosbuvir that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta330

Site by Devopa
© Copyright 2019 NHS. All rights reserved.